MoreBack to News Headlines



Experimental Alzheimer's drug could slow cognitive decline in patients, early results suggest
CNN
Eli Lilly and Company's experimental intravenous drug donanemab could slow the cognitive decline of patients with Alzheimer's disease, according to early clinical trial results, published in The New England Journal of Medicine on Saturday.
The study included 257 patients with early symptomatic Alzheimer's disease; 131 received donanemab, while 126 received a placebo. The researchers found donanemab slowed the decline of cognition and daily function in Alzheimer's patients by 32% after 76 weeks, compared to those who received a placebo. Taken over 18 months, that 32% slowing of decline could be noticeably impactful for Alzheimer's patients, noted Maria Carrillo, chief science officer at the Alzheimer's Association, who was not involved in the study.More Related News

Former President Joe Biden’s chief of staff, Ron Klain, told staffers on the House Oversight Committee that former National Security Adviser Jake Sullivan and former Secretary of State Hillary Clinton raised concerns to him in 2023 and 2024 about Biden’s political chances, two sources familiar with the matter said.

Ohio officer dies after shooter lying in wait ambushed police who parked to eat lunch, officials say
An officer in Ohio has died after a shooter lying in wait ambushed him and another officer as they parked to eat pizza in a remote, undeveloped area, Lorain police said Thursday.